In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473.

A novel sterically hindered platinum complex, AMD473 [cis-aminedichloro(2-methylpyridine) platinum (II)], has been selected for phase I clinical trials due to commence in 1997. AMD473 was rationally designed to react preferentially with nucleic acids over sulphur ligands such as glutathione. This re...

Descripción completa

Detalles Bibliográficos
Autores principales: Holford, J., Sharp, S. Y., Murrer, B. A., Abrams, M., Kelland, L. R.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151285/
https://www.ncbi.nlm.nih.gov/pubmed/9472630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151285/
https://www.ncbi.nlm.nih.gov/pubmed/9472630

Ejemplares similares